Billiontoone, Inc.
A molecular diagnostics company that reads cell-free DNA from a simple blood draw to offer ultrasensitive prenatal and cancer tests. Its UNITY prenatal portfolio screens for fetal conditions and antigens without needing a father's sample, while its Northstar oncology tests guide therapy choices and monitor response. Founded in 2016 by two scientists who met as Princeton roommates, the name "BillionToOne" captures the ability to spot a single DNA letter among the three billion in the human genome — and, the founders joke, it was the only domain name they could afford.
10-Q · Quarter ended Jun 30, 2026 · SEC filing ↗
growth slowed to 1% sequentially, the smallest quarter-over-quarter increase in two years. Revenue rose 64% to $109.4 million and was 70.5%, as a 21% increase in average selling price was partly offset by a mix shift toward higher-cost oncology tests. The company remains profitable, but the and decelerating top-line growth shift the focus to the oncology ramp and the planned Q4 MRD launch.
Revenue surged 64% YoY to $109.4M in Q2 2026, driven by 35% test volume growth and 21% higher ASP, swinging to net income of $8.1M.
Interest-rate, FX, and inflation risks are all deemed immaterial; no FX hedges are in place.
From time to time, we are involved in legal claims, regulatory investigations, inquiries, proceedings and other legal matters arising from the normal course of business and typical for our industry. Although no formal legal proceeding has been instituted, from time to time, we r…
From time to time, we are involved in legal claims, regulatory investigations, inquiries, proceedings and other legal matters arising from the normal course of business and typical for our industry. Although no formal legal proceeding has been instituted, from time to time, we receive requests from governmental agencies, or third parties working on their behalf, for documents and information related to our products. We do not view any of the legal claims, regulatory investigations, inquiries, proceedings and other legal matters that we are currently subject to as being material to our business; however, it is difficult to assess the outcome of these matters, and we may not prevail in any current or future proceedings or litigation. Litigation or any other legal, regulatory or administrative proceedings, regardless of the outcome, can result in substantial cost and diversion of our resources, including our management’s time and attention, and there can be no assurances that favorable final outcomes will be obtained. See Note 5 of our unaudited financial statements included in Part 1, Item 1 in this Quarterly Report on Form 10-Qfor more information concerning certain legal proceedings in which we are involved, which is hereby incorporated by reference. The resolution of any such legal proceeding is subject to inherent uncertainty and could have a material adverse effect on our financial condition, cash flows or results of operations.
Read original filing text →Investing in our Class A common stock involves a high degree of risk. In addition to the information set forth in this Quarterly Report on Form 10-Q, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our cons…
Investing in our Class A common stock involves a high degree of risk. In addition to the information set forth in this Quarterly Report on Form 10-Q, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes, you should consider carefully the factors discussed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on March 11, 2026. The occurrence of any of the risks and uncertainties described in such Annual Report could materially and adversely affect our business, financial condition, results of operations and prospects. In that event, the price of our Class A common stock could decline and you could lose part or all of your investment. Furthermore, such risks are not the only ones we face; additional risks and uncertainties not currently known or that we currently deem to be immaterial may also materially adversely affect our business, financial condition or results of operations.
Read original filing text →